Fosinopril
This ACE inhibitor lowers blood pressure by blocking the enzyme that produces angiotensin II, a potent blood vessel constrictor, allowing blood vessels to relax. It is used to treat high blood pressure and heart failure, and may offer protective benefits for the kidneys.
Moleküler Ağırlık
563,7000 g/mol
LogP
6,20
TPSA
110,00 Ų
Lipinski RO5
Başarısız
Terapötik Alanlar
Etki Mekanizması
Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.
2D Yapı
Cite this structure
Embed this structure
SMILES
CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C
InChI
InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30+,39-/m1/s1
Molecular Formula
C30H46NO7P
HBD / HBA
1 / 7
Döndürülebilir Bağlar
15
Ağır Atomlar
39
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
This ACE inhibitor lowers blood pressure by blocking the enzyme that produces angiotensin II, a potent blood vessel constrictor, allowing blood vessels to relax. It is used to treat high blood pressure and heart failure, and may offer protective benefits for the kidneys.
Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.
Yes, Fosinopril is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3039598. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9601226. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="fosinopril"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/fosinopril/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/fosinopril/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/fosinopril/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="fosinopril"></drugfyi-drug>